References
- Kadhe NG, Chillar AJ, Deshmukh YA. Reboxetine: A novel antidepressant. J Postgrad Med 2003; 49: 373–75
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Washington, DC: The American Psychiatric Association; 1994.
- Schule C, Baghai T, Schmidbauer S, et al. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 2004; 29: 185–200
- Schule C, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004; 79: 54–62
- Moeller O, Hetzel G, Michael N, et al. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram. Neuropsychobiology 2005; 51: 67–71
- Cleare AJ, Murray RM, O'Keane V. Do noradrenergic reuptake inhibitors affect serotonergic function in depression?. Psychopharmacology (Berlin) 1997; 134: 406–10
- Lin KC, Lee JN, Jong SB. Assessment of hypothalamic-pituitary function by hormonal pulsatility, gonadotropin-releasing hormone and thyrotropin-releasing hormone testing in women with euprolactinemic secondary amenorrhea. Kaohsiung J Med Sci 1998; 14: 698–705
- Harlow BL, Wise LA, Otto MW, et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2003; 1: 29–36
- Clark DWJ, Correa-Nunes A-M, Edwards IR. Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome). Eur J Clin Pharmacol 2003; 59: 261–62
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45